OligohydramniosNCT03935607
The Added Contribution of Transvaginal Sonographic Evaluation of Amniotic Fluid Index
An observational study of Oligohydramnios, run by Rambam Health Care Campus at 1 site in Israel.
Trial summary
The current study is based on the use of transvaginal sonography in the evaluation of oligohydramnios. Patients will be recruited after amniotic fluid index evaluation according to transabdominal sonography. Read more about this study
- Who is it for?
- Ages 18 to 45 years, women only
- Conditions the study is for
- Oligohydramnios
- What is being tested?
- Transvaginal sonography
- How many people
- 350 participants
- Where
- 1 siteIsrael
- Study dates
- 1 Jul 2019to 1 Apr 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Women only
- Adult
Study population: Women who meet the above inclusion criteria will be asked to participate in the study and to provide a written informed consent. This study, under no circumstances, will alter the participants routine care.
Who may be able to join
- Pregnant women at term beyond 37 weeks' gestation
- Presented to our hospital for their routine care or prior to induction of labor
- Singleton pregnancy
- Planned for vaginal delivery
- Non-laboring women with non-engaged fetal presenting part
Who cannot join
- Pregnant women under 37 weeks' gestation
- Planned cesarean deliveries
- Laboring women with engaged fetal presenting part
- Multiple gestation
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Pseudo-Oligohydramnios/Hidden Pocket Study: The Added Contribution of Transvaginal Sonographic Evaluation of Amniotic Fluid Index
The current study is based on the use of transvaginal sonography in the evaluation of oligohydramnios. Patients will be recruited after amniotic fluid index evaluation according to transabdominal sonography. After obtaining informed consent, transvaginal sonography will be used to evaluate and measure a possible amniotic fluid pocket that may precede the fetal presenting part.
Read the detailed description
Background Normal amniotic fluid volume varies across gestation (Ounpraseuth 2017). Abnormal amniotic fluid volume has been associated with a variety of adverse pregnancy outcomes (Shrem 2016). In clinical practice, the amniotic fluid volume is a component of the biophysical profile which provides information on fetal well-being.
Transabdominal ultrasound is used to assess quantitatively the amniotic fluid volume, most commonly by either the Amniotic Fluid Index (AFI) or the Maximum Vertical Pocket (MVP) methods.
The value of the AFI method has been questioned in several studies, which have shown that an abnormal test, low or high, is neither highly accurate nor predictive of adverse outcome. Many pregnancies with normal AFI will be falsely characterized as abnormal, and a large number with truly abnormal AFI will be missed (Magann 1994, Chauhan 1997).
The MVP measurement may be preferred over the AFI method. A 2008 systematic review of randomized trials found that use of the AFI increased the rate of diagnosis of oligohydramnios (RR 2.3), induction of labor (RR 2.1), and cesarean delivery for fetal distress (RR 1.5) (Nabhan 2008).
Rationale and Hypothesis of the Study Recently, our group observed that when transvaginal ultrasound is being performed to non-laboring pregnant women at term for other obstetrical indications, there is a large amniotic fluid pocket above the internal cervical os and below the fetal presenting part. Due to the unique location of this pocket, we hypothesized that transvaginal ultrasound may provide better information than transabdominal ultrasound on amniotic fluid volume, particularly in cases when suspecting abnormal low amniotic fluid volume.
Data Collection
- Maternal and fetal characteristics Data related to the fetomaternal antenatal, intrapartum and postpartum course will be recorded prospectively.
- Ultrasound assessment Each eligible woman in the study population group will be asked to undergo prenatal ultrasound examination twice. The first ultrasound examination is a routine transabdominal ultrasound examination that is carried out to assess fetal growth and well-being. This is to be continued with a second transvaginal ultrasound, with a specific focus on the amniotic fluid pocket, that is; the distance in centimetres between the fetal presenting part and the internal cervical os. The second transvaginal ultrasound will be performed for the purpose of the study only, and by one other research team member that is blinded to the first routine transabdominal ultrasound. The entire length of the study, combining the transabdominal and transvaginal ultrasounds, is expected to take on the average around 15 min.
Ultrasound Equipment and Safety Considerations In their 2011 statement, The International Society of Ultrasound in Obstetrics and Gynaecology (ISUOG) and World Federation of Ultrasound in Medicine and Biology (WFUMB) consider ultrasonography to be safe for use during clinical practice (ISUOG 2011).
Statistical analyses and sample size For sample size calculation, and given a 20% rate of induction of labor, of which 3% are due to abnormal low amniotic fluid volume (oligohydramnios), a sample size of 1000 women is required.
Feasibility of the Study Considering the high volume of maternal care here at Rambam Health Care Campus, and that every year there are around 5,000 births and nearly double routine cares, the recruitment process for the current study is feasible.
Expected Duration of the Study The recruitment for the study is expected to take place over 12 months with an additional 3-6 months after recruitment for data analysis before publication.
Funding Women will be recruited while approaching Rambam Health Care Campus for their routine obstetric care. Ultrasound examinations will be carried out using existing operational ultrasound equipments within the obstetric department at Rambam Health Care Campus. For both, the recruitment and the ultrasound examinations, no extra funding is currently required.
Public Health Interest Identifying new ultrasound variables that can assist in quantifying amniotic fluid volume, as the one suggested in the current study, is of great importance and may provide invaluable information into the overall future care and decision-making around the time of delivery, especially whether or not to induce labor in women with suspected oligohydramnios. Thus, it may assist in creating future recommendations for pregnant women and improved healthcare standards during the delivery process.
- Conditions
- Oligohydramnios
- Being tested
- Transvaginal sonography
- Medical subject headings
- Oligohydramnios
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Transvaginal sonographyDiagnostic test
Transvaginal sonography for the evaluation of an amniotic fluid pocket preceding the fetal presenting part.
| Study group | Role | What they receive |
|---|---|---|
| Normal amniotic fluid index | Patients with an amniotic fluid index of between 5-24 centimeters according to transabdominal sonography. Receives: Diagnostic Test: Transvaginal sonography | |
| Oligohydramnios | Patients with an amniotic fluid index of lss than 5 centimeters according to transabdominal sonography. Receives: Diagnostic Test: Transvaginal sonography |
What is being measured
The primary outcome is the main question the study is designed to answer.
Amniotic Fluid Fore-Pocket
Measurement of amniotic fluid pocket preceding fetal presenting part.
Measured: Up to 30 minutes from the beginning of patient evaluation.
Secondary outcomes (5)
Mode of delivery
Vaginal delivery, vacuum assisted delivery, cesarean section.
Measured: From time of induction up to 48 hours postpartum
pH level
Umbilical artery pH level
Measured: From the time of delivery up to 30 days postpartum
1 minute Apgar score
Neonatal 1st minute Apgar score
Measured: From the time of delivery up to 30 days postpartum
5 minute Apgar score
Neonatal 5th minute Apgar score
Measured: From the time of delivery up to 30 days postpartum
Neonatal intensive care unit admission
Rate of neonatal intensive care unit admission
Measured: From the time of delivery up to 30 days postpartum
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 May 2019
- Study start1 Jul 2019
- Primary completion31 Dec 2021
- Study completion1 Apr 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for OligohydramniosStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 350 participants (actual)
Sponsor and investigators
- Lead sponsor
- Rambam Health Care Campus
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, ROY LAUTERBACH MD, Rambam Health Care Campus
- Investigators
- Roy Lauterbach, MD, Principal investigator, Rambam Health Care Campus
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03935607
- Sponsor's protocol ID
- 0017-19-RMB
- Status last verified
- Apr 2022
- First submitted
- 25 Apr 2019
- Last updated
- 20 Apr 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 20 Apr 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Pseudo-Oligohydramnios/Hidden Pocket Study: The Added Contribution of Transvaginal Sonographic Evaluation of Amniotic Fluid Index
- ClinicalTrials.gov ID
- NCT03935607
- Acronym / sponsor ID
- 0017-19-RMB
- Conditions
- Oligohydramnios
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 350 participants (actual)
- Lead sponsor
- Rambam Health Care CampusUniversity, hospital or other
- Study start
- 1 Jul 2019 (actual)
- Primary completion
- 31 Dec 2021 (actual)
- Study completion
- 1 Apr 2022 (actual)
- First posted
- 2 May 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The current study is based on the use of transvaginal sonography in the evaluation of oligohydramnios. Patients will be recruited after amniotic fluid index evaluation according to transabdominal sonography. After obtaining informed consent, transvaginal sonography will be used to evaluate and measure a possible amniotic fluid pocket that may precede the fetal presenting part.
Detailed description
Background Normal amniotic fluid volume varies across gestation (Ounpraseuth 2017). Abnormal amniotic fluid volume has been associated with a variety of adverse pregnancy outcomes (Shrem 2016). In clinical practice, the amniotic fluid volume is a component of the biophysical profile which provides information on fetal well-being.
Transabdominal ultrasound is used to assess quantitatively the amniotic fluid volume, most commonly by either the Amniotic Fluid Index (AFI) or the Maximum Vertical Pocket (MVP) methods.
The value of the AFI method has been questioned in several studies, which have shown that an abnormal test, low or high, is neither highly accurate nor predictive of adverse outcome. Many pregnancies with normal AFI will be falsely characterized as abnormal, and a large number with truly abnormal AFI will be missed (Magann 1994, Chauhan 1997).
The MVP measurement may be preferred over the AFI method. A 2008 systematic review of randomized trials found that use of the AFI increased the rate of diagnosis of oligohydramnios (RR 2.3), induction of labor (RR 2.1), and cesarean delivery for fetal distress (RR 1.5) (Nabhan 2008).
Rationale and Hypothesis of the Study Recently, our group observed that when transvaginal ultrasound is being performed to non-laboring pregnant women at term for other obstetrical indications, there is a large amniotic fluid pocket above the internal cervical os and below the fetal presenting part. Due to the unique location of this pocket, we hypothesized that transvaginal ultrasound may provide better information than transabdominal ultrasound on amniotic fluid volume, particularly in cases when suspecting abnormal low amniotic fluid volume.
Data Collection
- Maternal and fetal characteristics Data related to the fetomaternal antenatal, intrapartum and postpartum course will be recorded prospectively.
- Ultrasound assessment Each eligible woman in the study population group will be asked to undergo prenatal ultrasound examination twice. The first ultrasound examination is a routine transabdominal ultrasound examination that is carried out to assess fetal growth and well-being. This is to be continued with a second transvaginal ultrasound, with a specific focus on the amniotic fluid pocket, that is; the distance in centimetres between the fetal presenting part and the internal cervical os. The second transvaginal ultrasound will be performed for the purpose of the study only, and by one other research team member that is blinded to the first routine transabdominal ultrasound. The entire length of the study, combining the transabdominal and transvaginal ultrasounds, is expected to take on the average around 15 min.
Ultrasound Equipment and Safety Considerations In their 2011 statement, The International Society of Ultrasound in Obstetrics and Gynaecology (ISUOG) and World Federation of Ultrasound in Medicine and Biology (WFUMB) consider ultrasonography to be safe for use during clinical practice (ISUOG 2011).
Statistical analyses and sample size For sample size calculation, and given a 20% rate of induction of labor, of which 3% are due to abnormal low amniotic fluid volume (oligohydramnios), a sample size of 1000 women is required.
Feasibility of the Study Considering the high volume of maternal care here at Rambam Health Care Campus, and that every year there are around 5,000 births and nearly double routine cares, the recruitment process for the current study is feasible.
Expected Duration of the Study The recruitment for the study is expected to take place over 12 months with an additional 3-6 months after recruitment for data analysis before publication.
Funding Women will be recruited while approaching Rambam Health Care Campus for their routine obstetric care. Ultrasound examinations will be carried out using existing operational ultrasound equipments within the obstetric department at Rambam Health Care Campus. For both, the recruitment and the ultrasound examinations, no extra funding is currently required.
Public Health Interest Identifying new ultrasound variables that can assist in quantifying amniotic fluid volume, as the one suggested in the current study, is of great importance and may provide invaluable information into the overall future care and decision-making around the time of delivery, especially whether or not to induce labor in women with suspected oligohydramnios. Thus, it may assist in creating future recommendations for pregnant women and improved healthcare standards during the delivery process.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Normal amniotic fluid index | – | Diagnostic Test: Transvaginal sonographyPatients with an amniotic fluid index of between 5-24 centimeters according to transabdominal sonography. |
| Oligohydramnios | – | Diagnostic Test: Transvaginal sonographyPatients with an amniotic fluid index of lss than 5 centimeters according to transabdominal sonography. |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Female only
- Age groups
- Adult
- Study population
- Women who meet the above inclusion criteria will be asked to participate in the study and to provide a written informed consent. This study, under no circumstances, will alter the participants routine care.
Key inclusion criteria (5 listed)
- Pregnant women at term beyond 37 weeks' gestation
- Presented to our hospital for their routine care or prior to induction of labor
- Singleton pregnancy
- Planned for vaginal delivery
- Non-laboring women with non-engaged fetal presenting part
Key exclusion criteria (4 listed)
- Pregnant women under 37 weeks' gestation
- Planned cesarean deliveries
- Laboring women with engaged fetal presenting part
- Multiple gestation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Transvaginal sonographyTransvaginal sonography for the evaluation of an amniotic fluid pocket preceding the fetal presenting part. | Diagnostic test | Normal amniotic fluid index, Oligohydramnios |
Primary outcome
Amniotic Fluid Fore-Pocket
Time frame: Up to 30 minutes from the beginning of patient evaluation.
Measurement of amniotic fluid pocket preceding fetal presenting part.
5 secondary outcomes
Mode of delivery
Time frame: From time of induction up to 48 hours postpartum
pH level
Time frame: From the time of delivery up to 30 days postpartum
1 minute Apgar score
Time frame: From the time of delivery up to 30 days postpartum
5 minute Apgar score
Time frame: From the time of delivery up to 30 days postpartum
Neonatal intensive care unit admission
Time frame: From the time of delivery up to 30 days postpartum
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Apr 2022.
- Individual participant dataSharing planned: Undecided
Related trials for Oligohydramnios
RecruitingPhase 4
Effect of LMWH on Neonatal Outcomes in Isolated Oligohydramnios
Oligohydramnios, Heparin
RecruitingPhase 3
A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
Autosomal Recessive Polycystic Kidney (ARPKD)
RecruitingObservational study
PPROM Registry (Preterm Premature Rupture of Membranes)
Fetal Membranes, Premature Rupture, Preterm Premature Rupture of the Membranes
Not yet recruiting
Impact of Enoxaparin Therapy on Fetal Outcomes in Intrauterine Growth Restriction
Intrauterine Growth Restriction
Recruiting
"Fetal gRowth AbnorMality dEtection Trial"
Small for Gestational Age Infant, Large for Gestational Age Infant
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Roy Lauterbach, MD principal investigator
Rambam Health Care Campus
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Oligohydramnios, run by Rambam Health Care Campus at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Apr 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Amniotic Fluid Fore-Pocket (time frame: Up to 30 minutes from the beginning of patient evaluation.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Apr 2022.